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Cancer is a major disease which has become the biggest
threat to human health due to its difficult early detection,
diagnosis, and treatment. According to the survey of the
World Health Organization in 2012, there were four million
new cancer cases and 8.2 million cancer-related deaths
worldwide. The history of treatment of tumors covered
traditional herbal medicines, surgical anatomy, antitumor
chemotherapy/radiotherapy, and new targeted drug therapy
and immunotherapy. In the past few decades, with the
rapid development of high-throughput technologies such as
microarrays and next-generation sequencing (NGS), increas-
ing in-depth studies of tumor biology were spurred at the
genetic and genomic level, leading to better targeted and
personalized healthcare solutions for cancer patients. The
successful implementation of the human genome project has
made people realize that genetic, environmental, and lifestyle
factors should be combined together to study cancer due to
its complexity. For example, some malignant tumors have
been proven to be related to the mutations of a drive gene
by using specific monoclonal antibodies and small molecule
compounds to block or suppress the relevant molecular
targets that can inhibit tumor growth and metastasis or
induce apoptosis; the survival time of patients has been
significantly extended.
The increasing availability and growth rate of “Big Data”
derived from various omics open a new window to improve
clinical diagnoses or therapeutics of cancer, but there are
many challenges in efficient analysis and interpretation of
such big and complex data. For instance, how to manage,
extract, analyze, integrate, visualize, and communicate the
hidden information from the myriad of data representations
of cancer evolved into one of the greatest challenges in next-
generation biomedicine. Thus, there is a need to fundamen-
tally address all the above-mentioned issues in Big Data in
cancer healthcare.
There are six interesting research papers in this special
issue coveringmachine learningmethods on feature selection
of gene expression profile, cancer prediction, potential new
drug design, and QSAR study of anticancer drugs.
Gene expression profiles provide a new insight into
cancer diagnosis at a molecular level which paved the way
towards personalizedmedicine. Gene expression data usually
contains a large number of genes, but a small number of
samples. Feature selection for gene expression data aims
at finding a set of genes that best discriminate biological
samples of different types. Q. Su et al. proposed a gene subset
selection algorithm based on the Kolmogorov-Smirnov (K-S)
test and correlation-based feature selection (CFS) principles
to address the challenging problem of selecting distinguished
genes from cancer gene expression datasets. The authors
compared the K-S test plus CSF with K-S test alone, CFS
alone, ReliefF, and mRMR feature selection in 5 cancer gene
expression datasets, which adopted support vector machines
(SVM) as the classification tool and used the criteria of
accuracy to evaluate the performance of the classifiers on the
Hindawi
BioMed Research International
Volume 2017, Article ID 1972097, 2 pages
https://doi.org/10.1155/2017/1972097
2 BioMed Research International
selected gene subsets. The results show that this combination
algorithm is more efficient.
L. Yang et al. presented a gene subset selection algorithm
RS_SVM based on aggregating SVMs trained on eight ran-
dom subspaces gene expression profiles.The results show that
RS_SVM outperforms single SVM, KNN, CART, Bagging,
AdaBoost, and 16 state-of-the-art methods in literatures. L.
Yang et al.’s study provides a potential tool for the problems of
high dimension and small sample problem in gene expression
data which could lead to overfitting and huge computing
pressure.The authors also proposed that RS_SVM is not suit-
able for heterogeneous data as they failed to apply RS_SVM
with PCA on two gene expression profiles.
Glioma is the most common and most aggressive malig-
nant brain tumor in humans that affects nonneural glial cells
in the central nervous system.The knowledge of glioblastoma
at the molecular and structural level will greatly improve
the treatment of glioma in the clinic. H. Long et al. made a
PPI network of key DEGs to study the significant functions
associated with the occurrence and development of glioma
combined with enriched GO and KEGG data. Pathways
in cancer, MAPK signaling pathway, focal adhesion, and
calcium signaling pathway were regarded to be related to the
occurrence of glioma. In addition, some key genes such as
MMP9, CD44, CDC42, COL1A1, COL1A2, CAMK2A, and
CAMK2B were also proposed, which might be target genes
for diagnosing glioblastoma.
EGFR is considered to be an anticancer target as it has
been found in some solid tumors, such as glioma, lung cancer,
ovarian cancer, breast cancer, and other cancers. Several
efforts have been made to develop EGFR inhibitors for the
treatment of cancer. The low selectivity, high toxicity, and
reduced activity promote the design of improved EGFR. M.
Zhao et al. introduced the application of 2D and 3D QSAR
methods to discriminate EGFR inhibitors and subsequently
performed structural docking of the molecules. Overall, this
study ismodest but nice which contributes to a deeper under-
standing of the intricacies of drug potency for inhibiting
EGFR.
J. Chen et al. developed a novel monocarbonyl cur-
cumin analog which exhibits preferable anticancer effects
on laryngeal cancer cells via targeting NF-𝜅B with little
toxicity to normal cells. Many traditional Chinese medicine
extracts have preferable anticancer effects; however, their
toxicities are usually neglected. Meanwhile, this study also
reveals that NF-𝜅B is probably a potential target for laryn-
geal cancer treatment using molecular docking method.
Therapeutics based on targeting NF-𝜅B may be effective
approaches for laryngeal cancer treatment in the future.
However, the results of this study all come from in vitro
trials; further tests of this curcumin analog in vivo need to be
performed.
M.C. Ng et al. built a bioactivity model for complex
mixtures of herb Radix Astragali (RA) extracts based on
chemical fingerprinting profiles with Elastic Net Partial Least
Square (EN-PLS) algorithm. The prediction platform they
obtained has the capacity to identify potential key bioactivity-
related chemical components of the herb, which is helpful for
discovering potential novel drugs, especially for the herbal
extracts to be used in clinical trials.
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